These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18427979)

  • 1. Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles.
    Yuvaraj S; Premkumar VG; Shanthi P; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Breast Cancer Res Treat; 2009 Mar; 114(2):377-84. PubMed ID: 18427979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
    Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins.
    Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Clin Biochem; 2007 Jun; 40(9-10):623-8. PubMed ID: 17425952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria.
    Perumal SS; Shanthi P; Sachdanandam P
    Chem Biol Interact; 2005 Feb; 152(1):49-58. PubMed ID: 15766922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Sathish S; Shanthi P; Sachdanandam P
    Vascul Pharmacol; 2008; 48(4-6):191-201. PubMed ID: 18407793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
    Premkumar VG; Yuvaraj S; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):387-91. PubMed ID: 17516992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Shanthi P; Sachdanandam P
    Br J Nutr; 2008 Dec; 100(6):1179-82. PubMed ID: 18377693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
    Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Biol Pharm Bull; 2007 Feb; 30(2):367-70. PubMed ID: 17268082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women.
    Dziewulska-Bokiniec A; Wojtacki J; Skokowski J; Kortas B
    Neoplasma; 1994; 41(1):13-6. PubMed ID: 8202188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.
    Ilanchezhian S; Thangaraju M; Sachdanandam P
    Cancer Biochem Biophys; 1995 Nov; 15(2):83-90. PubMed ID: 8590439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
    Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
    Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer.
    Perumal SS; Shanthi P; Sachdanandam P
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):105-14. PubMed ID: 15726365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy and tamoxifen after mastectomy in postmenopausal women -- 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I.
    Killander F; Anderson H; Rydén S; Möller T; Aspegren K; Ceberg J; Danewid C; Malmström P
    Eur J Cancer; 2007 Sep; 43(14):2100-8. PubMed ID: 17644330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
    Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
    Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of vitamin E on tamoxifen-treated breast cancer cells.
    Peralta EA; Viegas ML; Louis S; Engle DL; Dunnington GL
    Surgery; 2006 Oct; 140(4):607-14; discussion 614-5. PubMed ID: 17011908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids.
    Kailajärvi M; Ahokoski O; Virtanen A; Salminen E; Irjala K
    Anticancer Res; 2000; 20(2B):1323-7. PubMed ID: 10810443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer?
    Bhatavdekar JM; Patel DD; Karelia NH; Shah NG; Ghosh N; Vora HH; Suthar TP; Balar DB; Doctor SS
    Eur J Surg Oncol; 1994 Apr; 20(2):118-21. PubMed ID: 8181575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast cancer].
    Hoeller U; Borgmann K; Feyer P; Souchon R;
    Strahlenther Onkol; 2007 Oct; 183(10):535-44. PubMed ID: 17896084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.